Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$27,000.00
Is Extended Thromboprophylaxis After Major Abdominal Surgery for Cancer Worth the Risk? A New Perspective Using Target Trial Emulation
EF 2024-25
Résumé
Patients with cancer are at higher risk for developing blood clots especially in the weeks after having major abdominal surgery. This is an important cause of morbidity and death among cancer patients, therefore there is an urgent need for effective prevention. To reduce this risk numerous guidelines recommend a 28 day course of prophylactic anticoagulant medications. This is based on a review done by the Cochrane Database which showed statistically significant decrease in the occurrence of blood clots after surgery for cancer in those who took prophylactic anticoagulation. However, the generalizability of these findings have been questioned due to their use of screening ultrasound rather than testing symptomatic patients, and their length of follow up being 30 days, as the risk of blood clots is increased for up to 90 days after surgery. Given this uncertainty, there is a need to conduct a clinical trial.We will use a novel study design called Target Trial Emulation. In essence we will be applying population based data much like a retrospective cohort study, to the framework of a clinical trial. We will use data from Manitoba and Ontario. We will compare a sampling of our data to patient charts to ensure the data is of high quality. The target trial will be a non-inferiority trial which will study the intervention of filling a prescription for 28 day course of prophylactic anticoagulant medication versus none after leaving hospital. Outcomes studied will be symptomatic blood clots within 90 days of surgery, major bleeding, and overall survival.This study will provide important insight into current use and effects of prophylactic anticoagulants in patients undergoing major abdominal surgery for cancer, while also informing our future randomized controlled trial.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530055
Name
Fazel Darbandi Maziar
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Is Extended Thromboprophylaxis After Major Abdominal Surgery for Cancer Worth the Risk? A New Perspective Using Target Trial Emulation
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Abdominal Surgery; Anticoagulation; Cancer; Cancer Surgery; Complications; Pelvic Surgery; Population Based Data; Pulmonary Embolism; Target Trial Emulation; Venous Thromboembolism
Abstract
Patients with cancer are at higher risk for developing blood clots especially in the weeks after having major abdominal surgery. This is an important cause of morbidity and death among cancer patients, therefore there is an urgent need for effective prevention. To reduce this risk numerous guidelines recommend a 28 day course of prophylactic anticoagulant medications. This is based on a review done by the Cochrane Database which showed statistically significant decrease in the occurrence of blood clots after surgery for cancer in those who took prophylactic anticoagulation. However, the generalizability of these findings have been questioned due to their use of screening ultrasound rather than testing symptomatic patients, and their length of follow up being 30 days, as the risk of blood clots is increased for up to 90 days after surgery. Given this uncertainty, there is a need to conduct a clinical trial.We will use a novel study design called Target Trial Emulation. In essence we will be applying population based data much like a retrospective cohort study, to the framework of a clinical trial. We will use data from Manitoba and Ontario. We will compare a sampling of our data to patient charts to ensure the data is of high quality. The target trial will be a non-inferiority trial which will study the intervention of filling a prescription for 28 day course of prophylactic anticoagulant medication versus none after leaving hospital. Outcomes studied will be symptomatic blood clots within 90 days of surgery, major bleeding, and overall survival.This study will provide important insight into current use and effects of prophylactic anticoagulants in patients undergoing major abdominal surgery for cancer, while also informing our future randomized controlled trial.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fazel Darbandi, Maziar
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~